论文部分内容阅读
据《Lancet》1999年353卷第9171期报道 有愈来愈多的证据说明,HIV-1抗药性变异和药物失效相联系。直用基因型抗药性分析以对治疗失败病人做出治疗决定还没有人进行过研究。法国Archet医院感染病科J.Durant医生等,为对基因型抗药性试验的病毒学和免疫学影响作出评估,对使用联合疗法不成功的HIV-1感染病人进行了前瞻性、开放性随机对照研究。随机给予病人常规治疗(对照组,n=43)和按照蛋白酶及逆转录基因抗药性变异进行治疗(基因型组,n=65)。主要终点是HIV-1 RNA的病毒负荷变化,同时进行分折
As reported in Lancet, Volume 353, 1999, No. 9171, there is growing evidence that HIV-1 resistance mutations are linked to drug failure. Straight-line genotypic drug resistance analysis has not been studied in the treatment of failed patients. In an effort to assess the virological and immunological impact of genotypic drug resistance trials, Dr. J. Durant, Archet Hospital Infectious Diseases, France, conducted a prospective, open-label randomized controlled trial of HIV-1-infected patients unsuccessful with combination therapy the study. Patients were routinely treated (control group, n = 43) and treated with protease and RT-PCR variants (genotype group, n = 65). The primary endpoint is the change in viral load of HIV-1 RNA, with a breakdown at the same time